Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that the first patient has been dosed in the company’s Phase 2a RESET clinical trial evaluating JOTROL™ in patients with Parkinson’s disease (PD).

The dosing of the first patient represents an important clinical milestone for Jupiter and marks the transition of JOTROL™ into Phase 2a clinical evaluation in patients with Parkinson’s disease. The RESET study (NCT07592767) is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and biomarker effects of JOTROL™, Jupiter’s investigational, proprietary micellar formulation of trans-resveratrol.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.